• About us
    • Profile
    • Board of Directors
    • Scientific Directors
  • Our Science
    • Strategy
    • Activities and Technologies
  • Pipeline
    • Pipeline
    • Onco IX (PHC-102, Imaging)
    • 68Ga-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23
    • OncoFAP-GP-MMAE
    • OncoPSMA-GP-MMAE
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services
  • About us
    • Profile
    • Board of Directors
    • Scientific Directors
  • Our Science
    • Strategy
    • Activities and Technologies
  • Pipeline
    • Pipeline
    • Onco IX (PHC-102, Imaging)
    • 68Ga-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23
    • OncoFAP-GP-MMAE
    • OncoPSMA-GP-MMAE
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services

Philogen announces the publication of a new study in the European Journal of Nuclear Medicine and Molecular Imaging

by Lisa Nadal | Nov 11, 2022 | 2022, Past Events, Scientific

The study describes the discovery of GCPIII as the protein responsible for the accumulation of conventional PSMA targeting agents in healthy organs. More details

Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands

by Lisa Nadal | Nov 7, 2022 | 2022, Press Releases, Scientific

Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands isolated from DNA-Encoded Chemical Libraries. The novel OncoFAP ligands show a prolonged residence time in Fibroblast Activation Protein (FAP) positive tumors.   The...

Philogen publishes a new study on OncoFAP in Clinical Cancer Research

by Lisa Nadal | Oct 19, 2022 | 2022, Press Releases, Scientific

The study shows excellent tumor uptake of the novel OncoFAP-MMAE Small Molecule-Drug Conjugates (SMDCs) with high and selective release of the cytotoxic MMAE payload at the tumor site. OncoFAP-based pro-drugs are currently being developed for the imaging and therapy...

Philogen announces publication of IL12-7NP2 (an Interleukin-12 fusion protein against Fibroblast Activation Protein) in Journal for Immunotherapy of Cancer.

by Lisa Nadal | Sep 15, 2022 | 2022, Press Releases, Scientific

The study shows selective tumor uptake of IL12-7NP2 and potent antitumor activity as single agent and in combination with immune checkpoint inhibitors. The product is well tolerated when administered to non-human primates. More details

Philogen announces enrolment of 214 patients in the Nidlegy™ Phase III European clinical trial for the treatment of locally advanced melanoma

by m.romi | Jul 25, 2022 | 2022, Press Releases, Scientific

More details

Philogen to attend the 3rd Annual Cytokine-Based Drug Development Summit, Boston (July 26-29, 2022)

by Lisa Nadal | Jun 27, 2022 | 2022, Past Events, Scientific

Philogen will attend the 3rd Annual Cytokine-Based Drug Development Summit in Boston.   Roberto De Luca, Head of Antibody Therapeutics, will give a virtual lecture entitled “Antibody-cytokine fusion proteins against Fibroblast Activation Protein (FAP)” on the 28...
« Older Entries

Recent Posts

  • Philochem AG (a company of the Philogen group) announces the completion of central radiolabeling activities for the therapeutic use of OncoFAP-23
  • Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors
  • Philogen announces new publication in Nature Chemistry
  • Philochem to attend the 71st American Society for Mass Spectrometry Conference on June 4-8, 2023
  • Philogen to attend AACR Annual Meeting in Orlando on April 14-18, 2023

Recent Comments

    Philochem AG ©

    Privacy / Contacts

    • Follow

    Philochem AG | Libernstrasse 3 | CH-8112 | Otelfingen – Switzerand |MWST-Nr/VAT-REG: CHE-113.181.443 | Registration Nr. CH-020.3.030.226-7 Ph. (+41) 43 544 88 00 | Fax (+41) 43 544 88 09| info@philochem.ch